Trial Profile
Study to evaluate the mechanism of acquired resistance to Osimertinib with Circulating tumor DNA analysis in patients with advanced Non-small-cell-lung-cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Oct 2018
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
- 14 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology